%0 Journal Article
%A Riemenschneider, Markus J.
%A Fischer, Josephine
%A Grassow-Narlik, Maja
%A Mawrin, Christian
%A Deimling, Andreas von
%A Pietsch, Torsten
%A Reifenberger, Guido
%A Mueller, Wolf C.
%A Sommer, Clemens J.
%A Dietel, Manfred
%A Zoubaa, Saida
%A Lorenz, Julia
%A Rothhammer-Hampl, Tanja
%T Quality assurance in neuropathology: Experiences from the round robin trials on IDH mutation and MGMT promoter methylation testing launched by the Quality Assurance Initiative Pathology (QuIP) in 2018 and 2019
%J Clinical neuropathology
%V 39
%N 09
%@ 0722-5091
%C Deisenhofen, München
%I Dustri-Verl.
%M DZNE-2020-01419
%P 203 - 211
%D 2020
%X We here report on the first neuropathological round robin trials initiated by the Quality Assurance Initiative Pathology (QuIP) in Germany in the years 2018 and 2019. Testing services as external laboratory controls were offered for IDH1-R132H immunohistochemistry in 2018 followed by a molecular trial for IDH1 and IDH2 mutations in 2019 including the rare mutational variants. Also in 2019, a trial on MGMT promoter methylation testing was offered. On a national scale, trial offers were well received with around 40 participating institutions. The international announcement of the molecular IDH1/IDH2 mutational trial achieved only moderate European outspread. Success rates in all three trials were excellent (IDH1-R132H immunohistochemistry 2018: 94
%F PUB:(DE-HGF)16
%9 Journal Article
%R 10.5414/NP301278
%U https://pub.dzne.de/record/153422